A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants with Severe COVID-19

S
Samir Gupta, MD

Primary Investigator

Overview

The purpose of this study is to provide remdesivir (RDV) to participants with severe COVID-19.

Description

Participants will be randomly assigned to either continued standard of care therapy together with IV RDV 200 mg on Day 1 followed by IV RDV 100 mg on Days 2-5, or continued standard of care therapy together with IV RDV 200 mg on Day 1 followed by IV RDV 100 mg on Days 2-10.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    COVID-19
  • Age: Between 18 Years - 100 Years
  • Gender: All

Individuals at least 18 years of age hospitalized with a confirmed case of COVID-19.

Individuals with evidence of multiorgan failure, or those who have been mechanically ventialated for 5 or more days will not be eligible.

Women who are pregnant or breastfeeding will not be eligible.

Updated on 20 Nov 2022. Study ID: 2003892055

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center